Key result
Stages 3-5 CKD costs the English NHS ~£1.45 billion annually, or ~1.3% of total spending.
Answers are grounded in this paper and cite their sources.
BACKGROUND: Chronic kidney disease (CKD) is a major challenge for health care systems around the world, and the prevalence rates appear to be increasing. We estimate the costs of CKD in a universal health care system. METHODS: Economic modelling was used to estimate the annual cost of Stages 3-5 CKD to the National Health Service (NHS) in England, including CKD-related prescribing and care, renal replacement therapy (RRT), and excess strokes, myocardial infarctions (MIs) and Methicillin-Resistant Staphylococcus Aureus (MRSA) infections in people with CKD. RESULTS: The cost of CKD to the English NHS in 2009-10 is estimated at £ 1.44 to £ 1.45 billion, which is ≈ 1.3% of all NHS spending in that year. More than half this sum was spent on RRT, which was provided for 2% of the CKD population. The economic model estimates that ≈ 7000 excess strokes and 12 000 excess MIs occurred in the CKD population in 2009-10, relative to an age- and gender-matched population without CKD. The cost of excess strokes and MIs is estimated at £ 174-£ 178 million. CONCLUSIONS: The financial impact of CKD is large, with particularly high costs relating to RRT and cardiovascular complications. It is hoped that these detailed cost estimates will be useful in analysing the cost-effectiveness of treatments for CKD.
No takes yet. Share an insight, caveat, or question.
Kerr et al. (2012) studied Stages 3-5 Chronic Kidney Disease. Stages 3-5 Chronic Kidney Disease vs. Age- and gender-matched population without CKD was evaluated on Annual cost to the National Health Service in England. Stages 3-5 chronic kidney disease cost the English NHS an estimated £1.44 to £1.45 billion in 2009-10, representing approximately 1.3% of all NHS spending.
Synapse has enriched 10 related papers. Consider them for comparative context: